CA2411660C - Composes de promedicament a clivage enzymatique - Google Patents

Composes de promedicament a clivage enzymatique Download PDF

Info

Publication number
CA2411660C
CA2411660C CA2411660A CA2411660A CA2411660C CA 2411660 C CA2411660 C CA 2411660C CA 2411660 A CA2411660 A CA 2411660A CA 2411660 A CA2411660 A CA 2411660A CA 2411660 C CA2411660 C CA 2411660C
Authority
CA
Canada
Prior art keywords
seq
beta
leu
ala
oligopeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2411660A
Other languages
English (en)
Other versions
CA2411660A1 (fr
Inventor
Matthew H. Nieder
Vincent Dubois
Sanjeev Gangwar
Thomas J. Lobl
Lesley B. Pickford
Andre Trouet
Geoffrey T. Yarranton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of CA2411660A1 publication Critical patent/CA2411660A1/fr
Application granted granted Critical
Publication of CA2411660C publication Critical patent/CA2411660C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Ce promédicament est une forme modifiée d'un agent thérapeutique et comprend un agent thérapeutique, un oligopeptide, un groupe de stabilisation et éventuellement un groupe de liaison. Ce promédicament peut être clivé par la Thimet oligopeptidase, ou TOP. L'invention concerne également des procédés de conception de promédicaments comprenant l'introduction de séquences de clivage par TOP dans le conjugué, ainsi que des traitements comprenant l'administration des promédicaments décrits à des patients.
CA2411660A 2000-06-14 2001-06-11 Composes de promedicament a clivage enzymatique Expired - Fee Related CA2411660C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21188700P 2000-06-14 2000-06-14
US60/211,887 2000-06-14
US29044801P 2001-05-11 2001-05-11
US60/290,448 2001-05-11
PCT/US2001/018903 WO2001095945A2 (fr) 2000-06-14 2001-06-11 Composes de promedicament a clivage enzymatique

Publications (2)

Publication Number Publication Date
CA2411660A1 CA2411660A1 (fr) 2001-12-20
CA2411660C true CA2411660C (fr) 2011-03-01

Family

ID=26906558

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2411660A Expired - Fee Related CA2411660C (fr) 2000-06-14 2001-06-11 Composes de promedicament a clivage enzymatique

Country Status (5)

Country Link
EP (1) EP1294405A2 (fr)
JP (1) JP2004510703A (fr)
AU (2) AU7130101A (fr)
CA (1) CA2411660C (fr)
WO (1) WO2001095945A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
EP1404356B1 (fr) * 2001-06-11 2011-04-06 Medarex, Inc. Méthode pour concevoir des promédicaments activés par cd10
FR2858936A1 (fr) * 2003-08-22 2005-02-25 Diatos Potentialisation de l'activation de prodrogues de haut poids moleculaire
MX2009005776A (es) 2006-12-01 2009-06-10 Medarex Inc Anticuerpos humanos que se enlazan al cd 22 y sus usos.
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
WO2008074004A2 (fr) 2006-12-14 2008-06-19 Medarex, Inc. Anticorps humains se liant à cd70 et utilisations de ceux-ci
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
DK2976325T3 (en) 2013-03-21 2017-06-06 Sanofi Aventis Deutschland SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID
CA3203072A1 (fr) 2020-12-22 2022-06-30 Andrea CASAZZA Composes comprenant une fraction tetrapeptidique
WO2022167664A1 (fr) 2021-02-07 2022-08-11 Cobiores Nv Composés comprenant une fraction tétrapeptidique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0769967B1 (fr) * 1994-08-19 2007-12-12 La Region Wallonne Conjugues comprenant un agent antitumoral et leur utilisation
DK1144011T3 (da) * 1998-12-11 2010-07-05 Coulter Pharm Inc Pro-drug-forbindelser og fremgangsmåde til fremstilling deraf

Also Published As

Publication number Publication date
AU7130101A (en) 2001-12-24
AU2001271301B2 (en) 2006-08-31
CA2411660A1 (fr) 2001-12-20
EP1294405A2 (fr) 2003-03-26
JP2004510703A (ja) 2004-04-08
WO2001095945A3 (fr) 2002-08-15
WO2001095945A2 (fr) 2001-12-20

Similar Documents

Publication Publication Date Title
US8034787B2 (en) Enzyme-cleavable prodrug compounds
AU773420B2 (en) Prodrug compounds and process for preparation thereof
AU2001275525B2 (en) Tripeptide prodrug compounds
US7696313B2 (en) Prodrug compounds with isoleucine
AU2001275525A1 (en) Tripeptide prodrug compounds
ES2364452T3 (es) Método para diseñar compuestos profármacos activados por cd10.
US7893023B2 (en) Prodrugs activated by plasmin and their use in cancer chemotherapy
AU2001266853A1 (en) Prodrug compounds with an oligopeptide having an isoleucine residue
CA2411660C (fr) Composes de promedicament a clivage enzymatique
AU2001271301A1 (en) Prodrug compounds cleavable by thimet oligopeptidase

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed